Welcome to our dedicated page for GRI Bio SEC filings (Ticker: GRI), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Reading a biotech filing can feel like decoding a scientific journal. GRI Bio鈥檚 200-page annual report is packed with clinical trial data, cash-burn tables, and complex immune-modulation science that investors need but rarely have time to dissect. If you have ever searched for 鈥淕RI Bio SEC filings explained simply鈥� or wondered how to spot financing risk in the next 鈥淕RI Bio quarterly earnings report 10-Q filing,鈥� you are not alone.
Stock Titan solves that problem. Our AI reviews every GRI Bio document the moment it hits EDGAR, turning dense disclosures into plain-language briefs. Whether it is a 鈥淕RI Bio 8-K material events explained鈥� alert on a Phase 2 trial, or 鈥淕RI Bio insider trading Form 4 transactions鈥� highlighting real-time executive stock moves, you see the key points first.
Here is how investors use the page:
- Scan AI-powered summaries of the latest 10-K to find R&D spend, clinical milestones, and cash runway鈥斺�淕RI Bio annual report 10-K simplified.鈥�
- Compare quarter-over-quarter trial expenses with instant context inside each 10-Q鈥攐ur 鈥淕RI Bio earnings report filing analysis.鈥�
- Set alerts for 鈥淕RI Bio executive stock transactions Form 4鈥� to monitor confidence ahead of pivotal readouts.
- Review the proxy to understand 鈥淕RI Bio proxy statement executive compensation鈥� without wading through legal jargon.
All filing types鈥�10-K, 10-Q, 8-K, S-1, Form 4鈥攗pdate in real time. And because our platform explains immunotherapy terminology, you will finally feel comfortable 鈥渦nderstanding GRI Bio SEC documents with AI.鈥� Skip the scrolling; focus on decisions.
GRI Bio, Inc. filed a Form 8-K dated 31 July 2025 to disclose that it has issued a press release (Ex. 99.1) announcing interim biomarker data from its ongoing Phase 2a study of GRI-0621 in idiopathic pulmonary fibrosis (IPF). No numerical biomarker results, safety or efficacy data were included in the filing itself; investors must review the referenced press release for specifics. The company affirms its listing of common stock (ticker GRI) on Nasdaq and notes no other material transactions or financial updates. The item is reported under Item 8.01 鈥� Other Events; therefore it is considered informational rather than financial.
Nutex Health Inc. (NASDAQ: NUTX) filed an 8-K reporting the imminent departure of Chief Operating Officer Joshua DeTillio. Mr. DeTillio notified the company on July 8, 2025 that he will resign effective August 8, 2025 to accept a chief executive role elsewhere. The filing states that his resignation is not related to any disagreement with Nutex Health鈥檚 operations, policies, or practices. The Board of Directors has begun a comprehensive search for a successor. No other management or financial information was disclosed in this report.
GRI Bio (Nasdaq: GRI) furnished an 8-K under Item 7.01 disclosing a press release that reports interim safety results from its Phase 2a study of GRI-0621 for idiopathic pulmonary fibrosis. The disclosure is provided solely for Regulation FD purposes and is expressly not deemed 鈥渇iled鈥� under the Exchange Act. No efficacy data, financial metrics, or guidance updates were included. Exhibit 99.1 contains the full press release; no other material items were reported.
FAQ
What is the current stock price of GRI Bio (GRI)?
What is the market cap of GRI Bio (GRI)?
What is the primary focus of GRI Bio?
How do GRI Bio's therapies work?
What diseases are targeted by GRI Bio's products?
How does GRI-0621 function in treating liver disease?
What distinguishes GRI Bio from its competitors?
What potential does GRI-0803 have in addressing autoimmune disorders?
Does GRI Bio explore therapies beyond liver diseases?
How does the company ensure scientific and operational quality?
